Short answer
Gossamer Bio, Inc. (GOSS) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $13M (up 40.2% year over year) with net income of −$48M.
Q3 2025 key financials · XBRL
- Revenue
- $13M
- +40.2% YoY · +15.7% QoQ
- Net income
- −$48M
- −56.5% YoY · −26.0% QoQ
- Operating margin
- -369.4%
- EPS (diluted)
- −$0.21
- −61.5% YoY · −23.5% QoQ
Source: XBRL data from the Gossamer Bio, Inc. (GOSS) Q3 2025 10-Q on SEC EDGAR. USD.
Gossamer Bio, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $13.3M vs $9.5M YoY, up $3.8M from Chiesi collaboration payments
- Net loss $48.2M vs $30.8M YoY; operating margin -369.4% vs -358.1%
- Seralutinib R&D $45.5M vs $32.8M YoY; terminated programs $0 vs $2.1M
- Cash, equivalents and marketable securities $180.2M at September 30, 2025
- PROSERA enrollment completed; topline data expected February 2026, with continued operating losses anticipated
Risk Factors
- No risk-factors section provided in the submitted excerpt
- No newly added, updated, regulatory, operational, competitive, or financial risks identifiable from the text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gossamer Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.